Inclusion of health-related quality of life studies alongside clinical trials: Basis and practical recommendations. Utilization of a check-list for their correct desing and evaluation;Incorporación de estudios de calidad de vida relacionada con la salud en los ensayos clínicos: Bases y recomendaciones prácticas. Uso de una lista-guía para su correcto diseño y/o evaluación

Anales de Medicina Interna

Volumn 20, Issue 12, 2003, Pages 633-644

  Soto Alvarez J ^a,b  

^a Pharmacia SA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYSIS OF VARIANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVALUATION; HEALTH CARE DELIVERY; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PATIENT CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TECHNIQUE; VALIDATION PROCESS;

CLINICAL TRIALS; HEALTH STATUS INDICATORS; HUMANS; QUALITY OF LIFE; RESEARCH DESIGN;

EID: 0347719256     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Casa Anguita J, Repullo Labrador JR, Pereira Candal J. Medidas de calidad de vida relacionada con la salud. Conceptos básicos, construcción y adaptación cultural. Med Clin (Barc) 2001; 116: 26-33.
2. Farsides B, Dunlop RJ. Is there such a thing as a life not worth living? BMJ 2001; 322: 1481-1483.
3. Cella DF, Wiklund I, Shumaker SA, Aaronson NK. Integrating health-related quality of life into cross-national clinical trials. Qual Life Res 1993; 2: 433-440.
4. Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 2000; 53: 451-458.
5. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomized clinical trials: bibliographic study. BMJ 1998; 317: 1191-1194.
6. Chassany O, Bergmann JF, Caulin C. Reporting on quality of life in randomized controlled trials. BMJ 1999; 38: 1142.
7. Kong SX, Gaudhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997; 31: 830-836.
8. Revicki DA, Rothman M, Luce B. Health-related quality of life assessments and the pharmaceutical industry. PharmacoEconomics 1992; 1: 394-408.
9. Coons SJ, Kaplan RM. Assessing health-related quality of life: application to drug therapy. Clin Ther 1992; 14: 850-858.
10. Pocock SJ. A perspective on the role of quality of life assessment in clinical trials. Control Clin Trials 1991; 12 (Suppl): 257-265.
11. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
12. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-226.
13. Gill TM, Feinstein AR. A critical apparaisal of the quality of quality of life instruments. JAMA 1994; 272: 619-626.
14. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 1992; 45: 1341-1345.
15. Hays R, Hadorn D. Responsiveness to change: An aspect of validity, not a separate dimension. Qual Life Res 1992; 1: 73-75.
16. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality of life questionnaires. Pharmacoeconomics 2000; 17: 13-35.
17. Guyatt GH, Bombadier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Can Med Assoc J 1986; 134: 889-895.
18. Dowie J. Decisión validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. Health Econ 2002; 11: 1-8.
19. Fletcher A, Gore S, Jones D, Fiztpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care II: Design, analysis, and interpretation. Br Med J 1992; 305: 1145-1148.
20. Guyatt G, Feeny D, Patrick D. Issues in quality of life measurement in clinical trials. Control Clin Trials 1991; 12: 81S-90S.
21. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: Attributes and review criteria. Qual Life Res 2002; 11: 193-205.
22. Kirschner B, Guyatt GH. A methodologic framework for assessing health indices. J Chronic Diseases 1985; 38: 27-36.
23. Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996; 18: 979-992.
24. Testa MA, Nackley JF. Methods for quality-of-life studies. Ann Rev Public Health 1994, 15: 535-559.
25. Bergner M, Rothman ML. Health status measures: an overview and guide for selection. Ann Rev Public Health 1987; 8: 191-210.
26. Cramer JA for the ILAE Subcomission on Outcome Measurement in clinical trials. Epilepsia 2002; 43: 1084-1095.
27. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care I: Applications and issues in assessment. Br Med J 1992; 305: 1074-1077.
28. Rumsfeld JS, Whinney SM, McCarthy M, Shroyer AL, Villanueva CB, O'Brien M, et al. Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery. JAMA 1999; 281: 1298-1303.
29. Alonso J. La medida de la calidad de vida relacionada con la salud en la investigación y la práctica clínica. Gac Sanit 2000; 14: 163-167.
30. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991; 12: S142-S158.
31. Badia X, Carné X. La evaluación de la calidad de vida en el contexto del ensayo clínico. Med Clin (Barc) 1998; 110: 550-556.
32. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993; 2: 451-459.
33. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-1432.
34. Spilker B. Quality of life trials. In: Spilker B, ed. Guide to clinical trials. New York, NY. Raven Press; 1991: 370-378.
35. Simes RJ, Greatorex V, Gebski VJ. Practical approaches to minimize problems with missing quality of life data. Stat Med 1998; 17: 725-737.
36. Bernhard J, Cella DF, Coates CA, Fallowfield L, Ganz PA, Moinpour CH, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 1998; 17: 517-532.
37. Juniper EF. Quality of life questionnaires: does statistically significant = clinically important? J Allergy Clin Immunol 1998; 102: 16-17.
38. Lydick E, Epstein RS. Clinical significance of quality of life data. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996: 461-465.
39. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27 (Supl. 3): S1278-S189.
40. Fletcher A. Quality-of-life measurements in the evaluation of treatment: proposed guidelines. Br J Clin Pharmac 1995; 39: 217-222.
41. Offerhaus L. Measurement of the quality of life in clinical trials: in pursuit of the unapproachable. Eur J Clin Pharmacol 1991; 40: 205-208.
42. Fairclough DL, Gelber RD. Quality of life: Statistical issues and analysis. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA. Lippincott-Raven Publishers 1996; 427-435.
43. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ 1998; 316: 690-693.
44. Fletcher AE, Hunt BM, Bulpitt CJ. Evaluation of quality of life in clinical trials in cardiovascular disease. J Chron Dis 1987; 40: 557-566.
45. Cella DF, Wiklund I, Shumaker SA, Aaronson NK. Integrating health-related quality of life into cross-national clinical trials. Qual Life Res 1993; 2: 433-440.
46. Wiklund I. Practical issues in the design and inclusion of quality of life in multicenter clinical trials. Br J Med Econ 1993; 6C: 45-48.
47. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996; 5: 496-502.
48. Schumaker M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Stat Med 1991; 10: 1915-1930.
49. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000; 53: 459-468.
50. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures. Pharmacoeconomics 1999; 15: 141-155.
51. Wyrwich KW, Tierney WM, Wolinsky FD. Using the standard error of measurement to identify important changes on the asthma quality of life questionnaire. Qual Life Res 2002; 11: 1-7.
52. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 861-873.
53. Guyatt G, Osoba D, Wu A, Wyrwich K, Norman GR and the clinical significance consensus meeting group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.
54. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887-900.
55. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res 2002; 11: 207-221.
56. Schwartz CE, Sprangers MAG. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med 1999; 48: 1531-1548.
57. Curran D, Fayers PM, Molenperghs G, Machin D. Analysis of incomplete quality of life data in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of life assessment in clinical trials. New York, NY. Oxford University Press; 1998: 249-280.
58. Troxel AB, Fairclough DL, Curran D, Hahn EA. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 1998; 17: 517-532.
59. Fairclough DL, Gelber RD. Quality of life: Statistical issues and analysis. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA. Lippincott-Raven Publishers; 1996: 427-435.
60. Jennrich R, Schluchter M. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820.
61. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
62. Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med 1998; 17: 781-796.
63. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310: 452-454.
64. Juniper EF. The value of quality of life in asthma. Eur Resp Rev 1997; 49: 333-337.
65. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000; 18: 419-423.
66. Goldstein RS, Gort EH, Guyatt GH, Feeny D. Economic analysis of respiratory rehabilitation. Chest 1997; 112: 370-379.
67. Esparllargues M, Valderas JM, Alonso J. Provisión of feedback on perceived health status to health care professionals: a systematic review of its impact. Med Care 2000; 38: 175-186.
68. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patients-physician communication. A randomized controlled trial. JAMA 2002; 288: 3027-3034.
69. Revicki DA, Leidy NK, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotional. Value Health 1999; 2: 113-127.
70. Smith N. Quality of life studies from the perspective of an FDA reviewing statistician. Drug Inf J 1993; 27: 617-623.
71. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N fot the European regulatory issues on quality of life assessment group. Patient-reported outcomes: the example of health-related quality of life - A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002; 36: 209-238.